Too-Good-to-Be-True Wholesale Offer: DSCSA and Oregon Licensure
An independent Oregon pharmacy is short on a high-demand inhaler. A broker emails an offer for 200 units at 45% below the primary wholesaler's price, wire transfer only, no returns, and drop shipment from a warehouse in Delaware. The broker says it is 'licensed as a wholesale distributor in Delaware' and sends a certificate that does not list Oregon. The pharmacy's owner is tempted because patients are waiting. The boxes arrive with handwritten lot numbers, no 2D data matrix on the cartons, and a packing slip that does not match the invoice quantity. The pharmacy manager asks whether the staff can dispense the product once it is entered into inventory.
1. Before purchasing, what federal and Oregon checks must the pharmacy complete?
Read the worked answer
The pharmacy must treat this as a high-risk offer. Under the federal Drug Supply Chain Security Act, a dispenser may purchase prescription drug product only from an authorized trading partner, ordinarily the manufacturer, a licensed wholesale distributor, or a licensed repackager. The pharmacy must verify that the seller is licensed as a wholesale distributor in Oregon and in its home state, and must obtain transaction information, transaction history, and a transaction statement. The product must be serialized with a product identifier that includes the NDC, serial number, lot number, and expiration date. Oregon law separately requires a wholesale distributor license from the Oregon Board of Pharmacy; a Delaware license alone is not enough to distribute into Oregon. The wire-transfer-only demand, no-return policy, deep discount, and drop shipment are classic red flags. The pharmacy should not send money until licensure and DSCSA documentation are independently verified. A certificate that does not list Oregon is not proof of Oregon authority.
2. After the shipment arrives, may the pharmacy dispense the product? What should staff do with the boxes?
Read the worked answer
No. The shipment should be quarantined and not entered into saleable inventory or dispensed. The missing 2D data matrix, handwritten lot numbers, and invoice mismatch make the product suspect under DSCSA. The pharmacy should not try to 'fix' the labeling or assume the product is authentic because the boxes look normal. Staff should segregate the product in a secure, clearly labeled suspect-product area, preserve the shipping cartons and packing slip, and document the condition of the shipment. The pharmacy should contact the supplier in writing for the required transaction information and product identifier data. If the supplier cannot provide them, the pharmacy should not return the product to the supplier without instructions, because returning suspect product could put it back into the supply chain. The pharmacist-in-charge should be notified, and the pharmacy should follow its written suspect-product procedures before any further action.
3. What reporting and recordkeeping obligations apply if the pharmacy concludes the product is illegitimate or counterfeit?
Read the worked answer
The pharmacy should notify the supplier and the primary wholesaler as required by its DSCSA procedures and should report the suspect product to FDA using Form FDA 3911. If the product appears counterfeit, diverted, or intentionally adulterated, the pharmacy should also contact FDA's Office of Criminal Investigations and the Oregon Board of Pharmacy. The pharmacy should keep records of the purchase, the transaction information and statement, the quarantine, the notification, and the disposition of the product for at least six years under DSCSA recordkeeping requirements. The pharmacy should not dispense the product while the investigation is pending. If patients already received any of the product, the pharmacy should assess whether a recall or patient notification is needed and should consult the manufacturer and FDA. The pharmacist-in-charge should review the purchasing policy to prevent future purchases from unverified brokers.